...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current medical research and opinion >Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome
【24h】

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome

机译：Alosetron与临床实践中的传统药物治疗：对资源使用的影响，与严重腹泻的妇女的健康相关质量，安全性和症状改善 - 主要的肠易激综合征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Severe diarrhea-predominant irritable bowel syndrome (IBS-D) is associated with decreased health-related quality of life (HRQOL) and increased health care costs. Treatment recommendations for IBS-D often start with traditional pharmacotherapy (TP), with escalation to alosetron, rifaximin or eluxadoline if there is no success. There has been no previous head-to-head clinical trial comparing IBS-D treatment outcome for alosetron versus TP. This study, GSK protocol S3B30020, evaluated resource use, work productivity, health-related quality of life and global symptom response in women with IBS-D who were treated with alosetron or TP. Methods: A total of 1956 patients who met criteria for severe IBS-D were randomized to treatment with alosetron 1 mg twice daily (BID) or only TP for up to 24 weeks. Work productivity and resource use were evaluated by standard questionnaires, HRQOL by the IBSQOL instrument and IBS symptoms by the Global Improvement Scale (GIS). Results: Compared to only TP, alosetron-treated patients reported: (1) fewer clinic/office visits for any health problem (p = .0181) or for IBS-D (p = .0004); (2) reduced use of over-the-counter medications for IBS-D (p .0001); (3) fewer days of lost work productivity (p .0001); (4) decreased restriction of social and outdoor activities (p .0001); and (5) greater global improvement in IBS-D symptoms (p .0001). Alosetron treatment improved HRQOL scores for all domains (p .0001). Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported. Conclusions: Alosetron 1 mg BID significantly reduced health care utilization and lost productivity, and significantly improved global IBS symptoms, HRQOL, and participation in outdoor and social activities compared with treatment response to TP.
机译：目的：严重的腹泻主要肠易激综合征（IBS-D）与减少有关的健康有关的生命质量（HRQOL）和卫生保健成本增加。 IBS-D的治疗建议经常从传统药物治疗（TP）开始，如果没有成功，升级升高到aloSetron，Rifaximin或Eluxadoline。以前没有先前的头脑临床试验比较乙醛与TP的IBS-D治疗结果。本研究，GSK议定书S3B30020，评估资源使用，工作生产力，与ISSetron或TP治疗的IBS-D妇女的妇女的工作效率，生活质量和全球症状反应。方法：共有1956例符合严重IBS-D标准的1956名患者随机化以每日两次（BID）或仅TP含有两次的Alosetron1mg的治疗长达24周。通过全球改进量表（GIS）通过IBSQOL仪器和IBS症状进行标准问卷，HRQOL评估工作生产率和资源使用。结果：与仅TP相比，均血管菌治疗的患者报告：（1）对任何健康问题的诊所/办公室访问（P = .0181）或IBS-D（P = .0004）; （2）减少使用过柜内药物的IBS-D（P＆ .0001）; （3）工作率较少的日期较少（P <.0001）; （4）减少社会和户外活动的限制（P＆ .0001）; （5）IBS-D症状更大的全球改善（P <.0001）。 Alosetron治疗改善了所有结构域的HRQOL分数（P＆ .0001）。乙棘轮使用期间不良事件的发生率并不显着，并且与先前报道的相似。结论：Alosetron 1 Mg竞标显着降低了医疗保健利用率，损失了生产力，而且显着改善了全球IBS症状，HRQOL以及与TP的治疗反应相比的户外和社会活动。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号